Veinplicity at VAS 10th Congress

We enjoyed excellent conversations with all of the delegates dedicated to eradicating difficult venous access at the Vascular Access Society’s 10th Congress in Slovenia last week. Thanks to everyone who visited and shared their experiences and insights. We want to extend a special thank you to Nick Inston, Zaib Khawaja, Damian McGrogan and the rest of the Queen Elizabeth Hospital Birmingham team for studying the Veinplicity® device in autologous arteriovenous fistula creation for haemodialysis. They presented their favorable, early clinical results in a poster session, saying: “Veinplicity appears to be safe, well tolerated and provided easy intraoperative vessel identification”. Here’s Zaib, sharing details with nephrologist Maria Mesquita of CHU Brugmann. If you missed us in Ljubljana, we hope you’ll join us in Liverpool at the Royal College of Nursing Congress 2017 – May 13-16.


The Veinplicity device is CE marked and registered as a Class IIa medical device in the European Union and as a Class II medical device in Canada. We are seeking FDA approval. The device is manufactured within the ISO 13485 standard in the United States.

Featured Posts
Follow Veinplicity